Chi Sheng Pharma & Biotech Co (ROCO:4111) Cyclically Adjusted Revenue per Share: NT$21.46 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4111 Chi Sheng Pharma & Biotech Co Ltd ROCO:4111
85 GF Score
Price NT$30.15
GF Value NT$33.55
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Chi Sheng Pharma & Biotech Co Cyclically Adjusted Revenue per Share?

Chi Sheng Pharma & Biotech Co ROCO:4111 +0.33% 85 Cyclically Adjusted Revenue per Share is NT$21.46 as of Mar. 2026. GuruFocus rates ROCO:4111 with a GF Score™ of 85/100 and a GF Value™ of NT$33.55 (Modestly Undervalued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Chi Sheng Pharma & Biotech Co's adjusted revenue per share for the three months ended in Mar. 2026 was NT$5.891. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is NT$21.46 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Chi Sheng Pharma & Biotech Co's average Cyclically Adjusted Revenue Growth Rate was 4.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 2.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 4.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Chi Sheng Pharma & Biotech Co was 6.00% per year. The lowest was 2.60% per year. And the median was 3.70% per year.

As of today (2026-08-05), Chi Sheng Pharma & Biotech Co's current stock price is NT$30.15. Chi Sheng Pharma & Biotech Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was NT$21.46. Chi Sheng Pharma & Biotech Co's Cyclically Adjusted PS Ratio of today is 1.40.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Chi Sheng Pharma & Biotech Co was 1.74. The lowest was 1.11. And the median was 1.32.


Chi Sheng Pharma & Biotech Co  (ROCO:4111) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Chi Sheng Pharma & Biotech Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=30.15/21.46
=1.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Chi Sheng Pharma & Biotech Co was 1.74. The lowest was 1.11. And the median was 1.32.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Chi Sheng Pharma & Biotech Co Cyclically Adjusted Revenue per Share Related Terms


Chi Sheng Pharma & Biotech Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Chi Sheng Pharma & Biotech Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chi Sheng Pharma & Biotech Co Cyclically Adjusted Revenue per Share Chart

Chi Sheng Pharma & Biotech Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.19 19.43 19.84 20.27 20.99

Chi Sheng Pharma & Biotech Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.57 20.83 21.00 20.99 21.46

ROCO:4111 vs ISRG, BDX, MDLN: Cyclically Adjusted Revenue per Share Comparison

For the Medical Instruments & Supplies subindustry, Chi Sheng Pharma & Biotech Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chi Sheng Pharma & Biotech Co Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Chi Sheng Pharma & Biotech Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Chi Sheng Pharma & Biotech Co's Cyclically Adjusted PS Ratio falls into.


ROCO:4111
85GF Score
Chi Sheng Pharma & Biotech Co Ltd ROCO:4111
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chi Sheng Pharma & Biotech Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Chi Sheng Pharma & Biotech Co's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=5.891/330.2130*330.2130
=5.891

Current CPI (Mar. 2026) = 330.2130.

Chi Sheng Pharma & Biotech Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 3.978 241.018 5.450
201609 4.188 241.428 5.728
201612 4.131 241.432 5.650
201703 4.284 243.801 5.802
201706 4.179 244.955 5.634
201709 4.561 246.819 6.102
201712 4.307 246.524 5.769
201803 4.076 249.554 5.393
201806 3.910 251.989 5.124
201809 4.043 252.439 5.289
201812 4.027 251.233 5.293
201903 4.021 254.202 5.223
201906 4.338 256.143 5.592
201909 4.318 256.759 5.553
201912 4.424 256.974 5.685
202003 4.419 258.115 5.653
202006 3.885 257.797 4.976
202009 3.818 260.280 4.844
202012 4.016 260.474 5.091
202103 3.988 264.877 4.972
202106 4.326 271.696 5.258
202109 4.452 274.310 5.359
202112 4.319 278.802 5.115
202203 4.587 287.504 5.268
202206 4.659 296.311 5.192
202209 4.770 296.808 5.307
202212 4.959 296.797 5.517
202303 4.377 301.836 4.789
202306 4.437 305.109 4.802
202309 4.339 307.789 4.655
202312 4.493 306.746 4.837
202403 4.451 312.332 4.706
202406 4.701 314.175 4.941
202409 4.791 315.301 5.018
202412 5.485 315.605 5.739
202503 5.278 319.799 5.450
202506 6.149 322.561 6.295
202509 5.686 324.800 5.781
202512 5.698 324.054 5.806
202603 5.891 330.213 5.891

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of NT$21.46 mean?
Chi Sheng Pharma & Biotech Co (ROCO:4111) has a Cyclically Adjusted Revenue per Share of NT$21.46 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Chi Sheng Pharma & Biotech Co and its competitors.
Is Chi Sheng Pharma & Biotech Co's Cyclically Adjusted Revenue per Share too high?
Chi Sheng Pharma & Biotech Co's current Cyclically Adjusted Revenue per Share is NT$21.46. Overall, Chi Sheng Pharma & Biotech Co has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Chi Sheng Pharma & Biotech Co's Cyclically Adjusted Revenue per Share compare to ISRG and BDX?
Chi Sheng Pharma & Biotech Co's Cyclically Adjusted Revenue per Share of NT$21.46 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Chi Sheng Pharma & Biotech Co and its competitors. Chi Sheng Pharma & Biotech Co's current Cyclically Adjusted Revenue per Share is NT$21.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chi Sheng Pharma & Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Chi Sheng Pharma & Biotech Co (ROCO:4111) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$33.55, compared to a current price of NT$30.15 — trading 10.1% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is NT$21.46. Chi Sheng Pharma & Biotech Co's overall GF Score™ is 85/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Chi Sheng Pharma & Biotech Co (ROCO:4111), the current Cyclically Adjusted Revenue per Share is NT$21.46 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chi Sheng Pharma & Biotech Co (ROCO:4111) Overvalued in 2026?

Based on GuruFocus' analysis, Chi Sheng Pharma & Biotech Co stock appears to be undervalued. The current stock price of NT$30.15 is trading 10.1% below its estimated GF Value™ of NT$33.55. GuruFocus considers Chi Sheng Pharma & Biotech Co to be Modestly Undervalued.

Key valuation signals for ROCO:4111:

  • Cyclically Adjusted Revenue per Share: NT$21.46
  • GF Value™: NT$33.55 vs. price of NT$30.15 (10.1% below fair value)
  • GF Score™: 85/100 with 1 warning sign

No single metric tells the full story. See the ROCO:4111 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Chi Sheng Pharma & Biotech Co Business Description

Address No. 3, Shijian Road, Hsin Chu Industrial Park, Hsinchu County, Hukou, TWN, 30316
Chi Sheng Pharma & Biotech Co Ltd manufactures and distributes medical medicines and equipment in Taiwan. It offers injections, including hemodialysis solutions, amino acid injections, vitamin injections, and externally applied medicines.
85GF Score

Get the complete analysis for ROCO:4111

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$30.15
Price
NT$33.55
GF Value